The current two US Food and Drug Administration (FDA)-approved anti-BCMA chimeric antigen receptor (CAR)-T cells therapies for MM treatment rely on patients’ own peripheral blood T cells and can only be used for those patients. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.